It's here: the hearing starts tomorrow, and the FDA's scientists have already said no
The honest read on peptides — recovery, midlife, and beyond. What the evidence supports, what it doesn't, and what's just good marketing.
What does "compounding" actually mean?
You'll hear this word constantly this week, so it's worth two minutes. A compounding pharmacy makes a medication from raw ingredients for a specific patient with a prescription — rather than dispensing a mass-manufactured drug off the shelf. It's a legitimate, long-standing part of medicine: it's how you get a liquid version for someone who can't swallow pills, or a formula without a dye you're allergic to.
The crucial part: compounded drugs are not FDA-approved. The FDA approves drugs; compounding is a separate legal pathway where pharmacies may use ingredients from an approved list. So "legally compoundable" means "a pharmacy may prepare this for you" — it does not mean "the FDA has determined this works." Every headline this week hinges on that distinction, and most will blur it.
Tomorrow: the hearing — and the tension inside it
The FDA's Pharmacy Compounding Advisory Committee convenes July 23–24 at the White Oak campus in Silver Spring, Maryland, to review seven peptides — BPC-157, KPV, TB-500 and MOTS-c on day one; Emideltide (DSIP), Semax and Epitalon on day two — and vote on whether each belongs on the 503A bulks list. The public comment window closed today. The meeting is streamed publicly.
The FDA's own scientists have already answered. The agency's career reviewers applied the formal four-factor test — chemical characterization, history of use in compounding, evidence of effectiveness, and safety — and concluded that none of the seven satisfies the criteria. So the committee walks in tomorrow with its own agency's scientific staff recommending no across the board.
What to actually watch for. The committee is not obligated to follow the staff review, and the political leadership at HHS has spent the year signaling the opposite direction. So the question isn't really "will the evidence support approval" — the staff already answered that — it's whether the committee defers to the evidence review or to the policy climate. That's the story tomorrow, and it will tell you a lot about how peptide regulation goes for the next several years.
And keep the timeline honest. Even a unanimous yes doesn't put anything in a pharmacy soon: a PCAC vote is a non-binding recommendation, after which the FDA runs a formal notice-and-comment rulemaking that typically takes a year or more.
One thing to file away: a second PCAC meeting is expected before the end of February 2027, covering five more peptides — LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF. Two of those matter here: GHK-Cu is the copper peptide relevant to midlife skin, and Melanotan II is the "Barbie drug" tanning peptide with the melanoma concern. The regulatory story keeps coming closer to home.
The next GLP-1 is already being sold illegally — before it's approved
Retatrutide, a new triple-agonist from Eli Lilly, produced weight loss north of 25% of body weight in trials — results approaching bariatric surgery. It is genuinely exciting science. It is also not FDA-approved, and it is already being sold by some telehealth platforms and peptide vendors as a "compounded" product.
That's not a gray area — it isn't legal. Federal compounding rules require a drug to be FDA-approved or on the official shortage list; retatrutide is neither. Which means anything sold to you under that name has unverified purity, sterility, and dosing.
The keeper concept: this is the whole peptide problem in miniature. Real science, real promise, real Phase 2 data — and a marketplace that will sell it to you years before anyone knows whether it's safe at scale. Being excited about the research and refusing to buy it from a website are not contradictory positions. They're the only coherent one.
One of tomorrow's seven is actually about you
Among the peptides being voted on is MOTS-c — and unlike most of the recovery-focused compounds on the docket, it has a genuine midlife-women story. MOTS-c is a mitochondrial-derived peptide involved in metabolic regulation, and research has found its levels decline with age and estrogen loss, correlating with reduced skeletal-muscle insulin sensitivity and increased visceral fat in postmenopausal women. That maps almost exactly onto the metabolic shift so many women describe in midlife: same habits, different body.
So should you want MOTS-c injections? Here's the honest answer. Exogenous MOTS-c is in early-phase human trials — not commercially available, not proven, and the FDA's own review just said the human evidence isn't there. Meanwhile, there's a well-documented way to raise your MOTS-c that requires no prescription, no vendor, and no vote: exercise robustly increases the body's own MOTS-c. That may be one of the mechanisms by which physical activity protects metabolic health in aging women.
A fittingly on-brand note for hearing week: the compound is on trial tomorrow, and the intervention that reliably raises it is already free, available, and sitting in your week if you want it.
Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.
← All issues